On the BSE, 1.45 lakh shares were traded in the counter so far compared with average daily volumes of 74,000 shares in the past two weeks. The stock had hit a high of Rs 711.55 and a low of Rs 685 so far during the day.
Glenmark Pharmaceuticals announced today that its subsidiary Glenmark Arzneimittel GmbH has secured marketing authorization in Germany for Fluticasone/Salmeterol dry powder inhaler (DPI), a generic version of GlaxoSmithKline's Seretide Accuhaler. Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name SALFLUTIN.
Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. (Celon) in 2015 to develop and market generic Fluticasone/Salmeterol DPI in 15 European countries. The company has already launched this product in Denmark, Sweden and Norway. According to IQVIA data, Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of $844 million in Europe in the 12 month period ended March 2018.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)